Shanghai Twisun Bio-Pharm Co., Ltd.
Shanghai Twisun Bio-Pharm Co., Ltd. is a Chinese biopharmaceutical company established in 2007, positioned as a national high-tech enterprise that integrates research and development, production, sales, and after-sales service for advanced intermediates, active pharmaceutical ingredients (APIs), specialized chemicals, and natural medicines. The company operates from its headquarters in Shanghai’s Jinshan district, with production bases located in Anhui and Jiangxi provinces. The combined site footprint covers a substantial area and supports a large mobile workforce, underscoring its capacity to scale manufacturing and support export activities.
Twisun maintains a structured organizational framework and a core product system that focuses on cardiovascular, antiviral, antidiabetic, anticancer, and antifungal segments, as well as neurodegenerative disease-related compounds. The organization highlights more than 70 key intermediates spanning six major categories, including notable compounds such as Tenofovir, Ledipasvir, Sofosbuvir, Posaconazole, Saxagliptin, Vorapaxar, and LCZ696. This breadth reflects the company’s capability to manage complex chemical synthesis and scale-up processes that are essential for downstream supply chains in the pharmaceutical sector.
The company emphasizes a quality-driven philosophy and a service-oriented approach, positioning quality, customer-first policy, credit management, and professional services at the core of its operations. Twisun reports established relationships with a range of pharmaceutical enterprises domestically and internationally, with products exported to Europe, the United States, the Middle East, India, Southeast Asia, and other regions. The export activity indicates an existing engagement with international logistics frameworks and regulatory environments that govern cross-border pharmaceutical trade, including compliance with international standards and supply chain traceability.
Twisun’s corporate ethos is encapsulated in a customer-centric slogan that stresses understanding customer needs and striving to exceed expectations. The company expresses openness to collaboration with domestic and international partners to foster win-win outcomes. While the document provides an overview of manufacturing capabilities, product scope, and export reach, it does not contain specific information on logistics services, freight handling procedures, or dedicated freight forwarding capabilities. For organizations seeking to engage Twisun for international shipments of pharmaceutical intermediates or APIs, typical considerations would include regulatory compliance, batch documentation, transport stability of sensitive compounds, and coordination with licensed logistics providers to ensure proper handling and timely delivery across national borders.
As a potential partner for freight forwarding and logistics services, Twisun’s profile suggests a readiness to accommodate global distribution requirements for pharmaceutical ingredients, given its established export footprint and multi-site manufacturing network. Prospective logistics providers may wish to engage with Twisun to clarify prevailing packaging standards, batch traceability protocols, regulatory documentation, and preferred carriers or routes for European, North American, and Asian markets. Overall, the company presents as a substantial player in the biopharmaceutical sector with ongoing international trade activities and a commitment to quality and professional service.
